10-Q/A: ENDRA Life Sciences Amends Quarterly Report to Include Inline XBRL Tagging, Provides Business Update

ENDRA Life Sciences has amended its quarterly report for the period ended September 30, 2024, solely to add inline XBRL tagging, while also providing an update on its financial condition and business operations.

Summary

• ENDRA Life Sciences has filed an amendment to its Form 10-Q for the quarter ended September 30, 2024, to include inline XBRL tagging.
• The amendment does not reflect any subsequent events or modify disclosures from the original filing.
• The company is developing its TAEUS technology for non-invasive tissue characterization.
• ENDRA is focusing on commercializing its TAEUS FLIP system for non-alcoholic fatty liver disease (NAFLD).
• The company has not generated any revenue from its TAEUS technology as of September 30, 2024.
• Research and development expenses decreased to $2,552,336 for the nine months ended September 30, 2024, compared to $4,424,345 for the same period in 2023.
• The company reported a net loss of $7,358,943 for the nine months ended September 30, 2024, compared to a net loss of $8,600,714 for the same period in 2023.
• As of September 30, 2024, ENDRA had $4,745,187 in cash and an accumulated deficit of $99,289,095.
• The company needs additional capital to fund its operations and commercialization plans.
• ENDRA anticipates completing clinical studies by the fourth quarter of 2024 or first quarter of 2025 and submitting a new de novo request to the FDA in the first half of 2025.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including a lack of revenue, substantial losses, and a need for additional capital. While there is progress in development and regulatory efforts, the overall sentiment is negative due to the company's financial instability and dependence on future funding.

Positives

• Research and development expenses have decreased, indicating a shift towards commercialization.
• The company has raised capital through the issuance of common stock and warrants.
• ENDRA is actively working towards FDA approval for its TAEUS system.
• The company has a clear focus on the NAFLD application of its TAEUS technology.

Negatives

• The company has not generated any revenue from its TAEUS technology.
• ENDRA has a significant accumulated deficit of $99,289,095.
• The company is dependent on raising additional capital to continue operations.
• There is a material weakness in internal control over financial reporting due to insufficient personnel resources.
• The company has experienced significant losses and negative cash flow from operations.
• The company has a history of losses and limited commercial experience.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• There is a risk that the company may not be able to obtain FDA approval for its TAEUS system.
• The company faces competition in the medical device industry.
• There are uncertainties associated with clinical development and regulatory approvals.
• The company's financial condition and results of operations may be materially adversely affected if it cannot obtain sufficient financing.
• The company has a material weakness in internal control over financial reporting.

Future Outlook

The company anticipates completing clinical studies by the fourth quarter of 2024 or first quarter of 2025 and submitting a new de novo request to the FDA in the first half of 2025. The company expects to continue to incur significant expenses for the foreseeable future as it advances the development and commercialization of its TAEUS technology.

Management Comments

• Management is focused on obtaining adequate capital to fund operating losses until it establishes a revenue stream and becomes profitable.
• Management plans to continue as a going concern by raising additional capital through sales of equity securities and borrowing.
• Management believes that the company will need to raise substantial additional capital to complete the commercialization of its NAFLD TAEUS application.

Industry Context

The company is operating in the medical device industry, specifically focusing on non-invasive diagnostic technologies. The company's TAEUS technology is intended to compete with more expensive imaging technologies like CT and MRI, particularly in the diagnosis of NAFLD. The company is seeking to address a market need for more accessible and cost-effective diagnostic tools.

Comparison to Industry Standards

• ENDRA is a pre-revenue company, which is not uncommon for early-stage medical device companies.
• The company's focus on non-invasive diagnostics aligns with a broader trend in the medical device industry towards less invasive procedures.
• Compared to established medical device companies, ENDRA has significantly lower operating expenses and a much smaller market capitalization.
• Companies like Butterfly Network and Nano-X Imaging are also developing innovative medical imaging technologies, but with different approaches and target markets.
• The company's reliance on external funding is typical for companies in this stage of development, but it also presents a significant risk.

Management Changes

Related Party Transactions

• The company had a consulting agreement with director Alex Tokman.
• The company had transactions with PatentVest, a subsidiary of MDB Capital Holdings, where two board members have affiliations.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential equity offerings.
• Employees may be impacted by the company's financial instability.
• Customers and suppliers are affected by the company's ability to commercialize its products.
• Creditors are at risk due to the company's need for additional financing.

Next Steps

• Complete necessary clinical studies by the fourth quarter of 2024 or first quarter of 2025.
• Submit a new de novo request to the FDA in the first half of 2025.
• Continue to seek additional financing to fund operations and commercialization.
• Address the material weakness in internal control over financial reporting.

Key Dates

Keywords

TAEUS, NAFLD, Thermo-Acoustic Enhanced Ultrasound, FDA, Medical Device, Warrants, Reverse Stock Split, Clinical Trials, Financial Results, Capital Raise